Notice of Results

SkinBioTherapeutics PLC

08 March 2024

 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

Notice of HY results

Newcastle, UK - 8 March 2024 - SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, announces that the Company's interim financial results for the six months to
31 December 2023 will be released on Friday 22 March 2024.

The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the Investor Relations section of the Company's website: www.skinbiotherapeutics.com.

Stuart Ashman, CEO, and Manprit Randhawa, CFO will provide a live presentation via the Investor Meet Company platform at 12 noon on Friday 22 March 2024.

Questions can be submitted pre-event via the Investor Meet Company dashboard up to the day before the meeting or at any time during the live presentation. Investors who already follow SkinBioTherapeutics on the Investor Meet Company platform will automatically be invited.

Investors can sign up to Investor Meet Company for free at www.investormeetcompany.com/companies/skinbiotherapeutics-plc. 

-Ends-

For more information please contact:

SkinBioTherapeutics plc Stuart J. Ashman, CEO Manprit Randhawa, CFO	Tel: [phone]
Cavendish Capital Markets Limited (Nominated Adviser & Broker) Giles Balleny, Dan Hodkinson (Corporate Finance) Charlie Combe (Broking) Dale Bellis, Tamar Cranford-Smith (Sales)	Tel: [phone]
Instinctif Partners (Media) Melanie Toyne-Sewell / Jack Kincade	Tel: [phone] [e-mail]

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AxisBiotix-Ps™, a food supplement to address the symptoms of mild to moderate psoriasis.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com and www.axisbiotix.com.

 

END